Applications of (S)-2-Isocyanato-3-Phenylpropionic Acid Methyl Ester in Industrial Manufacturing

(S)-2-Isocyanato-3-Phenylpropionic Acid Methyl Ester serves as an advanced chiral intermediate for specialized chemical synthesis in pharmaceuticals, agrochemicals, and peptide production. Our factory supplies this product to clients running continuous and batch processing, where reliable quality and effective integration of this intermediate directly support regulatory approval and batch consistency. Below, the application block outlines the key industrial fields, reflecting scenario-specific integration, ratios, standards, and finished products.

1. Chiral Drug Intermediate Synthesis

Pharmaceutical manufacturers rely on this compound for stereoselective synthesis of non-proteinogenic amino acid derivatives integral to complex APIs. The material introduces a protected isocyanate moiety, essential in assembling chiral β-amino acid units. Process teams usually employ it at controlled temperature ranges with strict protection against moisture, entering after Boc or Fmoc-protection stages. Each campaign adjusts feed ratio based on analytical yield and impurity profile monitoring in line with DMF submissions for regulated markets.

Industry compliance standards

• ICH Q7 Good Manufacturing Practices for Active Pharmaceutical Ingredients
• US FDA 21 CFR Part 211
• EU GMP Guidelines Annex 13
• EP/BP/USP Pharmacopoeias for intermediate qualification

Typical usage ratio

• 0.85-1.10 molar equivalents per target API precursor, depending on enantiomeric excess requirements and process scale. Analytical adjustments made per batch by process QC.

Downstream process integration

• Stagewise addition following base-labile protecting group removal. Usually coupled under inert atmosphere with base-mediated nucleophilic substitution or amidation. Incorporation monitored by HPLC and chiral purity assessed in-process.

Final product types

• Stereochemically pure intermediates for antihypertensive agents
• Precursor moieties for DPP-IV inhibitor APIs (e.g., Sitagliptin analogues)
• Building blocks for oral β-lactamase inhibitors
• Specialty peptide fragments incorporated in research-stage oncology drugs

2. Specialty Agrochemical Active Ingredient Synthesis

Agrochemical formulators use this chiral isocyanate ester in multi-step synthesis routes for herbicide and fungicide actives, especially those requiring non-proteinogenic amino acid motifs for selective plant enzyme inhibition. The isocyanate function reacts selectively with designed aniline or carbamate building blocks to create target molecules with enhanced bioavailability and environmental persistence. Downstream integration typically follows deprotection, with NMR and LC-MS verification to ensure regulatory alignment for eventual pesticide registration.

Industry compliance standards

• FAO/WHO Specifications for Plant Protection Products
• ISO 9001:2015 for quality management system
• OECD Guidance for the Testing of Chemicals
• REACH Regulation (EC) No 1907/2006 for substance registration

Typical usage ratio

• 1.00 – 1.20 molar equivalents per functional core for target agrochemical actives; exact ratio determined by substrate reactivity and yield optimization during pilot trials.

Downstream process integration

• Introduced post-esterification and before final cyclization step. Operators maintain controlled temperature below 30°C to prevent side reactions, with continuous GC tracking of conversion and isomeric purity.

Final product types

• Selective broadleaf herbicides with chiral centers for reduced off-target toxicity
• Field-stable fungicidal active components
• Enantiomerically pure intermediates for insecticidal peptide mimics
• Key molecules in new generation seed treatments

3. Chiral Peptide and Oligopeptide Synthesis

Peptide API manufacturers select our chiral isocyanate methyl ester to build constrained peptide backbones and synthesize structurally defined oligopeptides. The raw material feeds into solid-phase or solution-phase peptide synthesis workflows, particularly for non-standard amino acid coupling. It enables the creation of protease-resistant peptides, applied in both therapeutic and advanced diagnostic agent pipelines. Plant teams emphasize trace impurity control and accurate timing of the addition step to minimize racemization and side chain isomer formation.

Industry compliance standards

• FDA cGMP for peptide APIs (21 CFR Part 210/211)
• USP <1047> Good Production of Peptide and Polypeptide Drugs
• ISO 13485:2016 for Medical Device-Related Peptides
• European Pharmacopoeia 2.7.8 for peptide purity

Typical usage ratio

• 0.95 – 1.05 molar equivalents relative to the previous peptide coupling partner per chain elongation step. Order of addition and stoichiometry based on batch size and target purity.

Downstream process integration

• Fed after completion of N-terminal deprotection, entering amidation or urea-formation stage. Reagent introduction scheduled to avoid intramolecular side reactions, with inline optical rotation monitoring used to supervise stereochemistry.

Final product types

• Orally available peptidomimetic drug leads
• Cyclic peptide antibiotics containing non-proteinogenic residues
• Hormone analogues resistant to enzymatic degradation
• Bioactive diagnostic peptides for immunoassays

4. Advanced Polymer Additive Synthesis

Functional materials and performance polymer producers introduce this ester into polycondensation or grafting reactions, where controlled chiral insertion modifies mechanical and surface properties of specialty plastics and resins. The isocyanate group enables reaction with diols or diamines to form urethane linkages with specific stereochemical configuration, supporting downstream applications like medical-grade elastomers and high-durability coatings. Production lines emphasize strict monomer purity and exotherm management to ensure consistent batch quality and performance.

Industry compliance standards

• ISO 10993-5 for Biocompatibility Testing of Medical Polymers
• ASTM D256 for Polymeric Material Impact Strength
• RoHS 2011/65/EU hazardous material control
• REACH Regulation for processed plastics

Typical usage ratio

• 0.5–3 wt% as a modifying comonomer in base polymer formulation. Proportions optimized for intended flexibility, tensile strength, or surface chemistry features according to end-use specification.

Downstream process integration

• Charged to reaction vessel after initiation of the main chain formation, monitored for full reaction of isocyanate and compatibility with catalyst systems. Batch records include FTIR end-point confirmation.

Final product types

• Medical implant base materials requiring precise chiral centers
• Wear-resistant elastomeric coatings for automotive parts
• Membranes for enantioselective separation processes
• Modified resins for high-end optical or electronic devices